Exact Sciences Corp (EXAS) concluded trading on Thursday at a closing price of $49.51, with 5.32 million shares of worth about $263.62 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -16.04% during that period and on February 20, 2025 the price saw a loss of about -1.92%. Currently the company’s common shares owned by public are about 185.08M shares, out of which, 182.06M shares are available for trading.
Stock saw a price change of -1.65% in past 5 days and over the past one month there was a price change of -8.75%. Year-to-date (YTD), EXAS shares are showing a performance of -11.89% which decreased to -18.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $40.62 but also hit the highest price of $79.62 during that period. The average intraday trading volume for Exact Sciences Corp shares is 2.11 million. The stock is currently trading -7.12% below its 20-day simple moving average (SMA20), while that difference is down -11.49% for SMA50 and it goes to -12.09% lower than SMA200.
Exact Sciences Corp (NASDAQ: EXAS) currently have 185.08M outstanding shares and institutions hold larger chunk of about 99.74% of that.
The stock has a current market capitalization of $9.16B and its 3Y-monthly beta is at 1.23. It has posted earnings per share of -$5.56 in the same period. It has Quick Ratio of 1.92 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EXAS, volatility over the week remained 5.09% while standing at 4.08% over the month.
Stock’s fiscal year EPS is expected to rise by 95.13% while it is estimated to increase by 357.74% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Barclays on January 23, 2025 offering an Overweight rating for the stock and assigned a target price of $70 to it. Coverage by Wells Fargo stated Exact Sciences Corp (EXAS) stock as an Overweight in their note to investors on August 28, 2024, suggesting a price target of $75 for the stock. On June 27, 2024, Scotiabank Initiated their recommendations, while on June 03, 2024, Jefferies Resumed their ratings for the stock with a price target of $75. Stock get a Buy rating from The Benchmark Company on January 02, 2024.
